MedDataX Logo

Clinical Study on the Treatment of Rhinitis Sicca With Sodium Hyaluronate Adjustable Nasal Irrigator

NCT ID: NCT07308015

Last Updated: 2025-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-16

Study Completion Date

2026-06-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To observe the therapeutic effect of sodium hyaluronate adjustable nasal irrigator on various types of rhinitis sicca and compare it with the therapeutic effect of the commonly used physiological seawater nasal spray in clinical practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rhinitis Sicca

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Physiological seawater adjustable nasal irrigator

Group Type ACTIVE_COMPARATOR

Physiological seawater adjustable nasal irrigator

Intervention Type DRUG

Nasal spray of Physiological seawater.

Experimental group

Sodium hyaluronate adjustable nasal irrigator

Group Type EXPERIMENTAL

Sodium hyaluronate adjustable nasal irrigator

Intervention Type DRUG

Nasal spray of Sodium hyaluronate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Physiological seawater adjustable nasal irrigator

Nasal spray of Physiological seawater.

Intervention Type DRUG

Sodium hyaluronate adjustable nasal irrigator

Nasal spray of Sodium hyaluronate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Symptoms: Dry nose sensation, little and thick nasal discharge, nosebleeds, itchy nasal cavity, and dryness in the nasopharynx. Physical signs: Nasal endoscopy often reveals dry and congested nasal mucosa, which appears grayish-white or dark red, losing its normal luster. There are often dry, thick secretions, scabs or blood scabs on it. The surface of the nasal mucosa is eroded and ulcers occur. The mucosal lesions are most obvious in the anterior part of the nasal cavity. A diagnosis can be made if one or more of the above symptoms and signs are present.

Exclusion Criteria

1. Those with dry rhinitis and chronic inflammation of the lower respiratory tract.
2. Those confirmed by examination to be caused by certain latent lesions in the mouth, nose, throat, esophagu.s, neck or the whole body
3. Those who have used drugs for treating dry rhinitis or other medications within the past 30 days.
4. Pregnant or lactating women.
5. Those who are allergic to this medicine.
6. Those with severe cardiovascular, liver, kidney and hematopoietic system diseases, etc.
7. Mentally ill patients.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

China-Japan Union Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dongdong Zhu

China-Japan Union Hospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

China-Japan Union Hospital of Jilin University

Changchun, Jilin, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Cuida Meng, Doctor

Role: CONTACT

Phone: 86+13596096000

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Liwei Sun, Doctor

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025052906

Identifier Type: -

Identifier Source: org_study_id